Page 28 - Sofinnova Partners News Today

/PRNewswire/ -- Muna Therapeutics ("Muna"), pioneering the development of novel, first-in-class small molecule therapeutics for neurodegenerative diseases,...

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the appointment of Geraldine Usseglio as Head of Human Resources. The creation

Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces...

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces a new translational science collaboration with

European venture capital firm has raised €1 billion in the last 12 months across its expanding life science investment platform Sofinnova Partners, a leading European life sciences venture capital

Collaborative team to progress novel USP30 DUB inhibitors to develop potential therapies for Parkinson's disease Mission Therapeutics ("Mission"), a drug discovery and development company focused

A record £3bn ($4bn) has been raised by the UK biotech and life science sector in the first three quarters of 2021.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!